R-DXd

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC, Daiichi Sankyo

Conditions

Lung NeoplasmSmall Cell Lung CarcinomaSolid Cancer

Phase 1

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

RecruitingNCT04938817

Merck Sharp & Dohme LLCSmall Cell Lung Carcinoma

Start: 2021-08-19End: 2029-12-10Target: 110Updated: 2026-03-19

Phase 2

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

RecruitingNCT06161025

Daiichi SankyoSolid Cancer

Start: 2024-02-27End: 2030-04-30Target: 860Updated: 2026-01-12

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

RecruitingNCT06780098

Merck Sharp & Dohme LLCLung Neoplasm

Start: 2025-05-28End: 2032-03-02Target: 144Updated: 2026-04-01

Related Papers

Abstract 1820: Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC).

Cancer Research2026-04-03

REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.

Journal of Clinical Oncology2025-05-28

Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors

2025-02-18

REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).

Journal of Clinical Oncology2024-06-017 citations

Abstract CT256: Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)

Cancer Research2024-04-052 citations